Fig. 3: HIPEC treatment restores the expression of miR-145-5p and modulates HIPEC-specific pathways in peritoneal metastatic lesions. | Cell Death & Disease

Fig. 3: HIPEC treatment restores the expression of miR-145-5p and modulates HIPEC-specific pathways in peritoneal metastatic lesions.

From: HSF-1/miR-145-5p transcriptional axis enhances hyperthermic intraperitoneal chemotherapy efficacy on peritoneal ovarian carcinosis

Fig. 3: HIPEC treatment restores the expression of miR-145-5p and modulates HIPEC-specific pathways in peritoneal metastatic lesions.The alternative text for this image may have been generated using AI.

A–E Scatter diagram graphs showing the expression of miR-145-5p, EGFR, OCT4, MYC, and MUC1, respectively, from the metastatic tissue samples during the time of the HIPEC treatment. p values are indicated on the graph. F Paired t-test analysis (two tailed) between the expression of miR-145-5p versus the HIPEC lesion samples at T90. Significantly different p < 0.05. G PCA plot shows the 3 patients considered in the RNA sequencing experiment distinguishing them in the various treatment times. In particular, the image highlighted the patients at T0 (blue oval) and T90 (yellow oval) time of CDDP perfusion. H The heat-map of differential expressed genes by RNA-seq between the indicated time of HIPEC treatment. The colors of the time of HIPEC treatment are indicated in the legend of the image.

Back to article page